Related content

Hormonal therapy for prostate cancer: primum non nocere

By Milbank A.J.   Dreicer R.   Klein E.A.  

Urology, Vol. 60, Iss. 5, 2002-11 ,pp. : 738-741

Elsevier

Access to resources Recommend Favorite

Medical management of benign prostatic hyperplasia

By Chacon A.   Monga M.  

Geriatric Nephrology and Urology, Vol. 9, Iss. 1, 1999-01 ,pp. : 39-48

Springer Publishing Company

Access to resources Recommend Favorite

Benign prostatic hyperplasia: a progressive disease of aging men

By Emberton M.   Andriole G.L.   de la Rosette J.   Djavan B.   Hoefner K.   Vela Navarrete R.   Nordling J.   Roehrborn C.   Schulman C.   Teillac P.   Tubaro A.   Nickel J.C.  

Urology, Vol. 61, Iss. 2, 2003-02 ,pp. : 267-273

Elsevier

Access to resources Recommend Favorite

Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications

By Lowe F.C.   Olson P.J.   Padley R.J.  

Urology, Vol. 54, Iss. 1, 1999-07 ,pp. : 81-85

Elsevier

Access to resources Recommend Favorite

Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy

By Kuo Hann-Chorng   Liu Hsin-Tzu  

Scandinavian Journal of Urology and Nephrology, Vol. 43, Iss. 3, 2009-04 ,pp. : 206-211

Informa Healthcare

Access to resources Recommend Favorite